Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations
STOCKHOLM — December 15, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmström has been appointed Director of Investor Relations. Linda has more than 15 years of experience from the life science industry. Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations. Rein Piir who